2008: RA Treatment: Small Molecules and Cell-Directed Biological Therapy
Search or Browse by Day

RA Treatment: Small Molecules and Cell-Directed Biological Therapy

Sunday, October 26, 2008
351
LX2931: A Potential Small Molecule Treatment for Autoimmune Disorders
352
Preclinical Characterization of INCB028050, JAK1/JAK2 Selective Clinical Candidate
353
Co-administration of an Oral JAK Inhibitor CP-690,550 and Methotrexate is Well Tolerated in Patients with Rheumatoid Arthritis
354
Anti-inflammatory Effects of BMS-582949, a P38 Mitogen Activated Protein Kinase (MAPK) Inhibitor, During Experimental Endotoxemia in Healthy Male Subjects
355
Multiple-Dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Potent P38 Inhibitor BMS-582949 in Healthy Subjects
356
Multiple Ascending Dose Study of a Potent p38 MAPK Inhibitor BMS-582949 in Subjects with Stable RA Receiving Concomitant Methotrexate
357
Potent Clinical Antiinflammatory and Analgesic Activity of a Novel p38α Inhibitor ARRY-797
358
ARRY-162, A Novel MEK Inhibitor: Results of a 14-Day Phase 1a Study in Healthy Subjects and a 28-Day Phase 1b Study in Rheumatoid Arthritis patients
359
ARRY-797, A Novel p38 MAP Kinase Inhibitor: Results of a 14-Day Phase 1 Study
360
Rituximab Effect On T Cell Populations Of Peripheral Blood From Rheumatoid Arthritis Patients
361
Long-Term Safety of Rituximab: 6-year Follow-up of the RA Clinical Trials and Re-treatment Population
362
Seven-Hundred and Fifty Patients Treated with Rituximab for RA in European Registries: Baseline Data Analysis from the Collaborative European REgistries for Rituximab in RA (CERERRA)
363
Efficacy and Safety of Various Dosing Regimens of Rituximab in Patients with Active RA: Results of a Phase III Randomized Study (MIRROR)
364
Efficacy and Safety of Rituximab (RTX) as First-Line Biologic Therapy in Patients (pts) with Active Rheumatoid Arthritis (RA): Results of a Phase III Randomized Controlled Study (SERENE)
365
Improved Quality of Life (QoL) With Rituximab (RTX) as First-Line Biologic Therapy in Patients (pts) With Active Rheumatoid Arthritis (RA): Results From a Phase III Randomized Controlled Study (SERENE)
366
Rituximab Fixed Retreatment versus On-Demand Retreatment in Refractory Rheumatoid Arthritis: Comparison of two B-cell depleting treatment strategies
367
Efficacy and Safety of Repeat Treatment Courses of Rituximab (RTX) in RA Patients (pts) with Inadequate Response (IR) to Tumor Necrosis Factor (TNF) Inhibitors: Long-term Experience from the REFLEX study
368
Continued Inhibition Of Structural Damage In Rheumatoid Arthritis Patients Treated With Rituximab At 2 Years: REFLEX Study
369
Evaluation Of Joint Damage In RA Patients Treated With Rituximab: Comparison Of Genant- And Van Der Heijde-modified Sharp Radiographic Scoring
370
Comparison of the Effectiveness of Rituximab and a Third TNF Blocking Agent after Failure of Two TNF Blocking Agents in Daily Clinical Practice
371
RA Patients Treated with Rituximab - Routine Care Data of the German Biologics Register RABBIT
372
Ofatumumab, a Human CD20 Monoclonal Antibody, in the Treatment of Rheumatoid Arthritis (RA): Subgroup Analysis at Week 24 From a Phase I/II Clinical Trial
373
Efficacy of Ofatumumab in Rheumatoid Arthritis (RA) Patients With Inadequate Response to One or More DMARDs: 48 Weeks Follow Up
374
TRU-015 Administered Every 24 Weeks for 2 Years is Well Tolerated and Maintains Consistent Pharmacodynamic Effects in Rheumatoid Arthritis Patients
375
Gene Profiling Studies Reveal that Abatacept Does Not Directly Induce Transcriptional Changes in Antigen-presenting Cells
376
A Subcutaneous Administration Regimen for Abatacept in Patients with Rheumatoid Arthritis: Pharmacokinetics, Safety and Immunogenicity
377
Time to Treatment Response with Abatacept in Patients with RA and an Inadequate Response to anti-TNF Therapy
378
Time to Treatment Response with Abatacept in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate
379
Safety and Efficacy of Abatacept Over 4 Years of Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate in the AIM Trial
380
Early Experience with Abatacept in a US Observational Cohort: Clinical and Patient Report Outcomes from the CORRONA Registry
381
12-Month Safety and Efficacy Data of a new Night-Time Release Prednisone for the Treatment of Rheumatoid Arthritis in 288 Patients
382
In Very Early Rheumatoid Arthritis Initial Aggressive Treatment With Methotrexate, Intra-articular Corticosteroid And Cyclosporine Or Placebo-Cyclosporine Resulted In 5 Years' Sustained Efficacy. Results From The CIMESTRA Study, An Investigator-Initiated,
383
Efficacy Of Every-other-week Methotrexate Schedule In Maintaining The Remission Of Patients With Rheumatoid Arthritis
384
Optimal Dosage and Route of Administration of Methotrexate in Rheumatoid Arthritis: a Systematic Review of the Literature
385
Pharmacokinetics of Oral MTX in RA Patients
386
Drug Monitoring Of Methotrexate In Rheumatoid Arthritis: Efficacy Profile Using Red Cell Methotrexate Polyglutamate Measurements
387
Contributors To Methotrexate Polyglutamate Levels In Patients With Rheumatoid Arthritis
See more of: ACR Abstract Submission Poster Sessions
<< Previous Session Level | Next Session Level >>